Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Montreal's Ventus Therapeutics

<< Previous

Bullboard Posts

Next >>

Comment by longterm56on Sep 29, 2022 6:18pm

128 Views

Post# 34996168

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Montreal's Ventus Therapeutics

Bucknelly is pointing out how far ahead Egrifta is ... with over a decade of safe use and approved to start a Phase 3 while the Ventus drugs have NOT EVEN STARTED clinical trials. Clearly there is something not attractive to Egrifta that is keeping partnerships at bay.

- LT

palinc2000 wrote:
I did not attempt to do a comparative analysis of the Nash data between the THTX and Ventus..
Can you share your findings?

Bucknelly21 wrote:
that's assuming you take paul for his word, not so sure i really do. If you have a company down the road with far less data safety ect sign a partnership you either arent having those talks or its just not a thing. And they need to stop acting as if they are trying.

palinc2000 wrote:
Financial markets in research targeting Nash including merger and acquisition potential are in revival mode in the last few weeks/months ....and the last Corporate Presentation mentions ''Actively pursuing discussions with companies that have interest ,capabilities and resources''

qwerty22 wrote:
Maybe "Not right now thanks" rather than never. But I think you've mostly got your expectations set right.

longterm56 wrote: If there is not enough interest in Egrifta for NASH to generate a partnership, do you really want THTX to go it alone? I'm sure big pharma has looked at it and has said, "no thanks". So why would they pursue it?

Lee430 wrote: If we did not have this potential high reward cancer platform would Thera have kept their eyes on the NASH prize and it would maybe be in PH3 by now instead of sending it to the time out chair?

Biobob wrote: I understand the frustration since I share it on a daily basis since 1998. I wprobably wont happen but we can hope a business update on October 13 delivers soemthing that makes Paul seemingly more verbal about Th1902...